The Alzheimer’s Drug Discovery Foundation has invested $5 million in Coya Therapeutics to help accelerate development and advance drugs to prevent, treat and cure Alzheimer’s disease and related dementias.
According to a company release, Coya’s lead therapeutic candidate, COYA 302, is being evaluated in multiple neurodegenerative diseases, including frontotemporal dementia (FTD). Funds from the ADDF are intended for a planned phase 2 clinical trial of the investigational, proprietary biologic combination therapy for those with FTD.
“We are grateful that a world-renowned